Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie Stakiw

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
British Journal of Haematology|February 9, 2021
Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group databaseVictor H Jimenez-Zepeda, Christopher Venner, Arleigh McCurdy, et al.
Cancer Medicine|September 26, 2022
Real-world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group DatabaseHira Mian, Richard LeBlanc, Martha Louzada, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 5, 2022
Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group DatabaseHira Mian, Donna Reece, Esther Masih-Khan, et al.
Current Oncology (Toronto, Ont.)|March 24, 2022
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) DatabaseArleigh McCurdy, Christopher P Venner, Esther Masih-Khan, et al.
European Journal of Haematology|February 4, 2021
The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myelomaHannah M Cherniawsky, Vishal Kukreti, Donna Reece, et al.
European Journal of Haematology|June 15, 2021
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in CanadaDonna E Reece, Esther Masih-Khan, Ehetu G Atenafu, et al.
Ejhaem|June 19, 2024
Long-term follow-up of outcomes including progression-free survival 2 in patients with transplant-ineligible multiple myeloma in the real-world practice: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) databaseRayan Kaedbey, Donna Reece, Christopher P Venner, et al.
Ejhaem|December 5, 2022
Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) DatabaseArleigh McCurdy, Martha Louzada, Christopher P Venner, et al.
European Journal of Haematology|August 13, 2023
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysisRichard LeBlanc, Hira Mian, Donna Reece, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 28, 2025
Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) AnalysisArleigh McCurdy, Engin Gul, Donna Reece, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
British Journal of Haematology|February 9, 2021
Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group databaseVictor H Jimenez-Zepeda, Christopher Venner, Arleigh McCurdy, et al.
Cancer Medicine|September 26, 2022
Real-world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group DatabaseHira Mian, Richard LeBlanc, Martha Louzada, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 5, 2022
Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group DatabaseHira Mian, Donna Reece, Esther Masih-Khan, et al.
Current Oncology (Toronto, Ont.)|March 24, 2022
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) DatabaseArleigh McCurdy, Christopher P Venner, Esther Masih-Khan, et al.
European Journal of Haematology|February 4, 2021
The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myelomaHannah M Cherniawsky, Vishal Kukreti, Donna Reece, et al.
European Journal of Haematology|June 15, 2021
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in CanadaDonna E Reece, Esther Masih-Khan, Ehetu G Atenafu, et al.
Ejhaem|June 19, 2024
Long-term follow-up of outcomes including progression-free survival 2 in patients with transplant-ineligible multiple myeloma in the real-world practice: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) databaseRayan Kaedbey, Donna Reece, Christopher P Venner, et al.
Ejhaem|December 5, 2022
Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) DatabaseArleigh McCurdy, Martha Louzada, Christopher P Venner, et al.
European Journal of Haematology|August 13, 2023
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysisRichard LeBlanc, Hira Mian, Donna Reece, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 28, 2025
Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) AnalysisArleigh McCurdy, Engin Gul, Donna Reece, et al.
Pageof 3